Gary Altwerger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gary Altwerger has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Davide Santin
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
17 shared publications - Masoud Azodi
Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences
14 shared publications - Peter E. Schwartz
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510
13 shared publications - Elena Ratner
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut
12 shared publications - Gloria Shining Huang
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510
12 shared publications - Stefania Bellone
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut
12 shared publications
Latest Publications
- Open Access
- 30 November 2024
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 56, 101652
Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins
- 30 November 2024
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 56, 101652
Open AccessUterine teratoma and the role of short-tandem repeat genotyping in understanding origins
- Open Access
- 9 May 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (9) , 1474-1475
Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail
A patient in her 60s presented with platinum-sensitive, oligometastatic, high-grade, serous ovarian cancer. Positron emission tomography (PET) scan showed a solitary lesion (2.5×3.0 cm, standardized uptake value (SUV) 15) in the splenic hilum extending to the pancreas. Key steps included pancreatic peritonectomy, proximal splenic vessel isolation, and mobilization of the pancreatic body and tail. The procedure was recorded using a 30° camera (supplemental materials).
- 9 May 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (9) , 1474-1475
Open AccessLaparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail
A patient in her 60s presented with platinum-sensitive, oligometastatic, high-grade, serous ovarian cancer. Positron emission tomography (PET) scan showed a solitary lesion (2.5×3.0 cm, standardized uptake value (SUV) 15) in the splenic hilum extending to the pancreas. Key steps included pancreatic peritonectomy, proximal splenic vessel isolation, and mobilization of the pancreatic body and tail. The procedure was recorded using a 30° camera (supplemental materials).
- Open Access
- 6 May 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (10) , 1651-1652
Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region
- 6 May 2024
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 34 (10) , 1651-1652
Open AccessConventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 9 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1768-1777
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Purpose: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine (9vHPV) versus clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) patients. Patients and Methods: We randomly allocated 133 patients with untreated CIN2/3 in equal proportions to a 4-month treatment with self-applied vaginal suppositories containing imiquimod (Arm B) or imiquimod plus a 9vHPV (Arm C) versus clinical surveillance (Arm A). The main outcome was efficacy, defined as histologic regression to CIN1 or less. Secondary outcomes were HPV clearance and tolerability. Exploratory objectives included the comparison of cervical CD4/CD8 T-cell infiltration at baseline, mid-study, and posttreatment by flow cytometry among study arms. Results: Of the 114 evaluable patients 77% and 23% harbored CIN2 and CIN3, respectively. Regression to CIN1 or less was observed in 95% of patients in the imiquimod group (Arm B) compared with 79% in the control/surveillance (Arm A); P = 0.043 and 84% in the imiquimod+9vHPV group (Arm C; P = 0.384 vs. Arm A). Neither of the treatment-arm differences from Arm A reached the prespecified α = 0.025 significance level. No significant differences were noted in the secondary outcome of rate of HPV clearance. The number of tissue-resident memory CD4/CD8 T cells in cytobrush samples demonstrated a >5-fold increase in Arm B/imiquimod when compared with Arm A/surveillance (P < 0.01). In contrast, there was no significant difference in T-cell responses among participants in Arm C when compared with Arm A. Imiquimod treatment was well tolerated. Conclusions: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.
- 9 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1768-1777
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Purpose: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine (9vHPV) versus clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) patients. Patients and Methods: We randomly allocated 133 patients with untreated CIN2/3 in equal proportions to a 4-month treatment with self-applied vaginal suppositories containing imiquimod (Arm B) or imiquimod plus a 9vHPV (Arm C) versus clinical surveillance (Arm A). The main outcome was efficacy, defined as histologic regression to CIN1 or less. Secondary outcomes were HPV clearance and tolerability. Exploratory objectives included the comparison of cervical CD4/CD8 T-cell infiltration at baseline, mid-study, and posttreatment by flow cytometry among study arms. Results: Of the 114 evaluable patients 77% and 23% harbored CIN2 and CIN3, respectively. Regression to CIN1 or less was observed in 95% of patients in the imiquimod group (Arm B) compared with 79% in the control/surveillance (Arm A); P = 0.043 and 84% in the imiquimod+9vHPV group (Arm C; P = 0.384 vs. Arm A). Neither of the treatment-arm differences from Arm A reached the prespecified α = 0.025 significance level. No significant differences were noted in the secondary outcome of rate of HPV clearance. The number of tissue-resident memory CD4/CD8 T cells in cytobrush samples demonstrated a >5-fold increase in Arm B/imiquimod when compared with Arm A/surveillance (P < 0.01). In contrast, there was no significant difference in T-cell responses among participants in Arm C when compared with Arm A. Imiquimod treatment was well tolerated. Conclusions: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.